An Evaluation of Bone Mineral Density in HIV-1-infected Adult Subjects Switching From a Tenofovir-containing Antiretroviral Therapy Regimen to a Dolutegravir Plus Rilpivirine Regimen
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Apr 2017
At a glance
- Drugs Dolutegravir/rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Registrational
- Sponsors ViiV Healthcare
- 27 Sep 2016 Planned End Date changed from 1 Sep 2018 to 1 Aug 2018.
- 26 Jan 2016 Planned End Date changed from 1 Aug 2018 to 1 Sep 2018, according to ClinicalTrials.gov record.
- 26 Jan 2016 Planned primary completion date changed from 1 Aug 2018 to 1 Sep 2018, according to ClinicalTrials.gov record.